Virax Biolabs Group Ltd [NASDAQ: VRAX] traded at a high on 2025-12-03, posting a 75.11 gain after which it closed the day’ session at $0.69.
The results of the trading session contributed to over 294218253 shares changing hands. Over the past one week, the price volatility of Virax Biolabs Group Ltd stands at 20.17% while the volatility over the past one month is 11.89%.
The market cap for VRAX stock reached $2.99 million, with 6.54 million shares outstanding and 3.90 million shares in the current float. Compared to the average trading volume of 241.83K shares, VRAX reached a trading volume of 294218253 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Virax Biolabs Group Ltd [VRAX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRAX shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRAX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Virax Biolabs Group Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 31, 2025.
The Price to Book ratio for the last quarter was 0.85, with the Price to Cash per share for the same quarter was set at 0.77.
How has VRAX stock performed recently?
Virax Biolabs Group Ltd [VRAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 69.83. With this latest performance, VRAX shares gained by 26.94% in over the last four-week period, additionally sinking by -27.58% over the last 6 months – not to mention a drop of -69.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRAX stock in for the last two-week period is set at 72.86, with the RSI for the last a single of trading hit 0.0861, and the three-weeks RSI is set at 0.0613 for Virax Biolabs Group Ltd [VRAX]. The present Moving Average for the last 50 days of trading for this stock 0.5502, while it was recorded at 0.4552 for the last single week of trading, and 0.8772 for the last 200 days.
Virax Biolabs Group Ltd [VRAX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Virax Biolabs Group Ltd [VRAX] shares currently have an operating margin of -196566.68% and a Gross Margin at -14976.66%. Virax Biolabs Group Ltd’s Net Margin is presently recorded at -189001.71%.
Virax Biolabs Group Ltd (VRAX) Capital Structure & Debt Analysis
According to recent financial data for Virax Biolabs Group Ltd. ( VRAX), the Return on Equity (ROE) stands at -80.87%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -74.46%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Virax Biolabs Group Ltd’s Return on Invested Capital (ROIC) is -100.99%, showcasing its effectiveness in deploying capital for earnings.
Virax Biolabs Group Ltd (VRAX) Efficiency & Liquidity Metrics
Based on Virax Biolabs Group Ltd’s (VRAX) latest financial statements, the Debt-to-Equity Ratio is 0.10%, indicating its reliance on debt financing relative to shareholder equity.
Virax Biolabs Group Ltd (VRAX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Virax Biolabs Group Ltd. (VRAX) effectively leverages its workforce, generating an average of -$296842.11 per employee. The company’s liquidity position is robust, with a Current Ratio of 11.35% and a Quick Ratio of 11.21%, indicating strong ability to cover short-term liabilities.
Insider trade positions for Virax Biolabs Group Ltd [VRAX]
There are presently around $6.05%, or 6.59%% of VRAX stock, in the hands of institutional investors. The top three institutional holders of VRAX stocks are: VIRTU FINANCIAL LLC with ownership of 28058.0 shares, which is approximately 1.3984%. HRT FINANCIAL LP, holding 25672.0 shares of the stock with an approximate value of $$29000.0 in VRAX stocks shares; and HRT FINANCIAL LP, currently with $$12761.0 in VRAX stock with ownership which is approximately 0.5483%.
